sellWeak cluster of 2
Ansbert Gadicke sold $132k of TCRR
director, owner at TCR2 THERAPEUTICS INC.. 70,170 shares at an average of $1.88, traded May 22, 2023, filed May 24, 2023.
Warning score
39Value
$132k
70,170 shares
Holdings after
304,001
-19% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +11Trade size$132k at market
- +5Share of holdings soldSold 19% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-23-031888, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 22, 2023 | XIn-the-money exercise Common Stockindirect: See Footnote | +178,269 | $0.74 | $132k | 374,171 | May 24, 2023 |
| May 22, 2023 | SOpen-market sale Common Stockindirect: See Footnote | -70,170 | $1.88 | $132k | 304,001 | May 24, 2023 |
| May 22, 2023 | XIn-the-money exercise Common Stock Warrant (Right To Buy)derivativeindirect: See Footnote | -42,761 | $0.00 | $0 | 0 | May 24, 2023 |
| May 22, 2023 | XIn-the-money exercise Common Stock Warrant (Right to Buy)derivativeindirect: See Footnote | -135,508 | $0.00 | $0 | 0 | May 24, 2023 |
Related signals
Other insiders at TCR2 THERAPEUTICS INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | TCRRbuy TCR2 THERAPEUTICS INC. | Kevin C Tang owner | $86k 50,000 shares | +1% | |
| 36Weak | TCR2 THERAPEUTICS INC. | Mpm Asset Management LLC owner | $132k 70,170 shares | -19% | |
| 31Weak | TCRRbuy TCR2 THERAPEUTICS INC. | Kevin C Tang owner | $88k 44,948 shares | +1% | |
| 33Weak | TCRRbuy TCR2 THERAPEUTICS INC. | Kevin C Tang owner | $164k 83,988 shares | +2% | |
| 39Weak | TCRRbuy TCR2 THERAPEUTICS INC. | Kevin C Tang owner | $548k 289,577 shares | +7% | |
| 15Weak | TCR2 THERAPEUTICS INC. | Alfonso Quintas Cardama Chief Medical Officer | $15k 13,799 shares | -11% | |
| 15Weak | TCR2 THERAPEUTICS INC. | Angela Justice Chief People Officer | $9,448 8,620 shares | -15% | |
| 31Weak | TCR2 THERAPEUTICS INC. | Garry E Menzel President and CEO | $35k 31,938 shares | -19% | |
| 15Weak | TCR2 THERAPEUTICS INC. | Peter Olagunju Chief Technical Officer | $5,299 4,830 shares | -17% | |
| 10Weak | TCR2 THERAPEUTICS INC. | Alfonso Quintas Cardama Chief Medical Officer | $10k 7,942 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.